Volibo 300 mcg (Tablet)
Unit Price: ৳ 8.00 (3 x 10: ৳ 240.00)
Strip Price: ৳ 80.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Voglibose |
| Company | Sun pharmaceutical bangladesh ltd |
| Also available as |
Indications
- Reduction in Post-Prandial Hyperglycaemia (PPHG)
- Non-insulin-dependent diabetes mellitus (NIDDM) patients immunotherapy
- Combination with other Oral Hypoglycaemic Agents (OHAs)
- Prevention of onset of type 2 diabetes mellitus
- Elderly patients and those with hepatic dysfunction or renal impairments
- Glycogen storage disease prevention
- Non-diabetic Hyperinsulinemia treatment
- Steroid induced diabetes mellitus treatment
Description
- General properties similar to acarbose
- Selective inhibition of α-glucosidase in the enteric canal
- Suppression of sharp increase in post-prandial plasma glucose
Pharmacology
- Competitive inhibitors of enzymes needed to digest carbohydrates
- Blocks pancreatic alpha-amylase
- Reduction in the rate of digestion of complex carbohydrates
Dosage & Administration
- Usually orally administered in a single dose of 0.2 mg, 3 times a day
- Pediatrics safety and effectiveness not established
- Lower starting dose recommended for geriatrics
Interaction
- Careful administration with antidiabetic drugs
- Drugs enhancing the hypoglycaemic action
- Drugs diminishing the hypoglycemic action
Contraindications
- Hypersensitivity to Voglibose or excipients
- Diabetic ketoacidosis, diabetic pre-coma
- Severe infection, serious trauma
- Gastrointestinal obstruction
Side Effects
- Diarrhea, loose stools, abdominal pain
- Constipation, loss of appetite, nausea, vomiting
- OHAs plus Volibo may cause hypoglycemia
- Fulminant hepatitis, serious liver dysfunction, jaundice
- Numbness, edema, blurred vision, weakness, hyperkalemia
Pregnancy & Lactation
- Safety not established in pregnancy
- Not recommended for lactating and nursing mothers
Precautions & Warnings
- Careful administration in patients receiving other antidiabetic drugs
- Caution in patients with chronic intestinal disease or hepatic/renal dysfunction
Use in Special Populations
- Poorly absorbed after oral doses
- No dose adjustment required in renal failure
Overdose Effects
- Transient increase in flatulence, diarrhea, abdominal discomfort
- No systemic reactions expected
Therapeutic Class
- Alpha-Glucosidase inhibitor
Storage Conditions
- Cool and dry place
- Protect from light